Hunter Immunology starts national lung disease vaccine trial

22-Mar-2011 - Australia

Hundreds of Australian patients are set to trial a new oral vaccine designed to help people plagued by chronic respiratory infections, predominantly during winter.

Scientists at Hunter Immunology have developed a treatment for Chronic Obstructive Pulmonary Disorder, or COPD, which is being trialled on up to 340 patients at major hospitals around the country.

Recruitment is now underway at 23 sites, including The Austin Hospital, The Alfred and the Royal Melbourne in Victoria, St Vincents Hospital and the Prince of Wales Hospitals in Sydney and both Royal Brisbane and Royal Perth Hospitals.

The drug HI 164OV is taken orally and works by stimulating the immune system to alleviate the flare ups commonly occurring in patients with moderate to severe disease.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance